Skip to main content

Military Health System

Test of Sitewide Banner

This is a test of the sitewide banner capability. In the case of an emergency, site visitors would be able to visit the news page for addition information.


Shingles Vaccine Resource Center


Shingles is caused by the varicella zoster virus, the same virus that causes chickenpox. Shingles infection occurs when the virus reactivates decades after initial infection, and affects approximately one in three persons in the general population during their lifetime. Shingles is characterized by a localized, often severely painful cutaneous eruption that can last weeks or months, and occurs most frequently in older adults.

Shingles vaccine is licensed for adults ages 50 and older. The current recommendation, however, remains to routinely immunize adults 60 years and older with a one-time dose of shingles vaccine. The vaccine can be given to people who have already had an episode of shingles. Check with your doctor to see if the vaccine is needed or if it will be covered by individual medical insurance policies.

Source: Centers for Disease Control and Prevention

Resource Center

You will find below all of the resources you will need about the shingles vaccine. More will be added as they are published or released.

Information Paper Date
Shingles Disease and Shingles Vaccine Feb. 5, 2018
Standing Orders Date
Zoster Vaccine (Adult)
June 2022
Vaccine Information Statements (VIS) Date
Recombinant Zoster (Shingles) Vaccine, RZV: What You Need to Know
Feb. 4, 2022
Manufacturer Package Inserts Date
July 23, 2021
Zostavax (Frozen)
Feb. 21, 2019
Zostavax (Refrigerated)
Feb. 21, 2019
Advisory Committee on Immunization Practices (ACIP) Recommendations Date
Shingles Vaccine
Jan. 21, 2022

You also may be interested in...

MMQC-19-1557 GlaxoSmithKline (GSK) Shingrix Vaccine Shortage/Additional Guidance


Due to continued high demand, additional instructions and guidance have been issued for Medical Treatment Facilities (MTFs) ordering Shingrix shingles vaccine.

Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018


Shingrix, a recombinant zoster vaccine, was licensed in October 2017. Early post-licensure safety monitoring findings are consistent with prelicensure clinical trial data. Serious adverse events were rare, and no unexpected patterns were detected.

Notes from the Field: Vaccine Administration Errors Involving Recombinant Zoster Vaccine — United States, 2017–2018


Early monitoring indicates that vaccine provides might confuse administration procedures and storage requirements of the older Zostavax and newer Shingrix shingles vaccines.

QuickStats: Percentage of Adults Aged ≥60 Years Who Ever Had the Shingles Vaccine, by Sex — National Health Interview Survey, 2008–2016


The percentage of adults aged ≥60 years who ever had the shingles vaccine increased from 6.7% in 2008 to 33.4% in 2016. Women were more likely than men to have had the shingles vaccine.

MMQC-18-1648 GlaxoSmithKline Shingrix Shortage


The purpose of this message is to provide disposition instructions on shipping delays for Shingrix (zoster recombinant, adjuvanted) vaccine.

MMQC-18-1396 Pharmaceutical Reverse Distributor Program Acceptance of Live Attenuated Shingles Vaccine (Zostavax)


Medical treatment facilities (MTFs) may now turn in soon-to-expire Zostavax shingles vaccine to potentially receive a credit on their Prime Vendor account.

Shingrix vaccine storage labels


Examples of proper storage, handling and reconstitution of Shingrix recombinant shingles vaccine.

Shingles Disease and Shingles Vaccine

Fact Sheet

This information paper describes the Herpes Zoster (Shingles) disease and vaccine to prevent it.

Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines


Revised recommendations for use of shingles vaccines following the October 2017 approval of a new vaccine.

Varicella (Herpes) Zoster Vaccine Update - Recommendations and Usage

  • Identification #: N/A
  • Date: 7/25/2011
  • Type: Directives
  • Topics: Shingles
Page 1 of 1 , showing items 1 - 10
Last Updated: May 05, 2023
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery